Announcement PDF patrys.com 1 Bridging Gaps in Therapeutic Care TechKnow Presentation July 2026 ASX:PAB Disclaimer The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Patrys nor any other entity or person in or associated with the Patrys group of companies guarantees any return (whether capital or income) or generally the performance of Patrys or the price at which its securities may trade. In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Patrys securities. It is not for general distribution or third party reliance or use. While it has been prepared from sources Patrys believe to be reliable, Patrys cannot guarantee its accuracy or completeness and undertakes no obligation to advise of changes or updates to any such materials. These materials are not exhaustive of all of the information a potential investor or their professional adviser would require. Nor do these materials take into account any specific objectives, financial situation or needs of investors. In addition, the past performance of Patrys cannot be assumed as indicative of the future performance of the company. For these and other reasons, before making any investment decision regarding Patrys securities you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk. Where this presentation does contain any forward looking statements, those statements are only made as the date of the presentation and are to be considered “at-risk statements” not to be relied upon as they are subject to further research and to known and unknown risks, uncertainties and other factors that may lead to actual results differing from any forward looking statement. This is particularly the case with companies such as Patrys which operate in the field of researching, discovering, developing, and commercialising potential drugs intended for safe and effective for human treatments or therapies. 2 A Faster, Lower-Risk Path to a >US$2B Delirium Market Reformulating a proven drug to deliver a faster, lower-risk path to market Proven Drug Reformulated for ICU Accelerated Development Pathway ✓ Quetiapine already widely used in clinical practice ✓ Safety and efficacy well understood ✓ Extensive human clinical data available ✓ New proprietary Injectable formulation with patent protection extending to ~20421 ✓ Immediate onset vs oral dosing ✓ Suitable for ICU, palliative and aged care settings ✓ FDA 505(b)(2) regulatory pathway ✓ 3–5 year development timeline ✓ ~$20–30M development cost vs ~$1.2B for new drugs Traditional Biotech Patrys Reformulation New molecule discovery Known drug reformulated 10–15 years 3–5 years ~$1.2B ~$20–30M 3 Patrys Limited (ASX:PAB) Executive & Board of Directors Peter Christie CHAIRMAN • 25+ years ASX governance and board experience • Chairman of multiple ASX-listed companies • Current Chairman of ASX:MOH and Non- Executive Director of ASX:MRD. Leanne Kite DIRECTOR • Capital markets, finance and investor relations executive with 20+ years’ experience • Investor relations for ASX 200 lithium producer Liontown Resources • Co-founder Reliis Dino Cercarelli DIRECTOR • Clinical trial and healthcare operations leader • COO of Australian Clinical Trials Alliance • Co-founder of Reliis Brian Leedman DIRECTOR • Biotech entrepreneur with strong ASX healthcare track record • Co-founder of ResApp Health (acquired by Pfizer) • Chairman or Director of multiple ASX-listed companies including Blinklab, Alcidion, Oncosil and NeuroScientific Biopharmaceuticals. Dr Anton Uvarov DIRECTOR • Healthcare and biotech investment specialist • Former Citigroup healthcare equities analyst • Co-founder and director of multiple ASX-listed companies, including BlinkLab (ASX:BB1), Elsight (ASX:ELS), Dimerix (ASX:DXB), Actinogen (ASX:ACW) and Neuroscientific Biopharmaceuticals (ASX:NSB). ASX Governance Biotech Commercialisation Capital Markets, Finance & Investor Relations Clinical Trial Operations Healthcare & Biotech Investment Combining drug development, commercialisation and capital markets expertise 4 Dr Samantha South CEO • Extensive CNS medical research background • Founding Director and COO of Argenica • 10 yrs Director experience at multiple companies • Technology transfer and commercialisation in medtech / biotech over 15 yrs Therapeutic Development Delirium: Severe and Acute Brain Dysfunction Delirium: Severe and Acute Brain Dysfunction Cognitive Decline Confusion Disorientation Altered Thinking & Behavious 3 Forms • Withdrawn (Hypoactive) • Mixed • Aggressive (Hyperactive) 1 Richardson et al., Age and Ageing 2021; 50: 914–920 Up to 80% of ICU patients experience delirium Increased Risk Of Dementia1 5 Patrys Limited (ASX:PAB) Estimated Serviceable Addressable Market >US$2 Billion per year The Problem: Current Treatment Challenges 6 • No approved drug treatments# • Current treatments used “ OFF-LABEL” • Oral quetiapine difficult to administer to delirium patients “OFF-LABEL” Antipsychotic & Benzodiazepine • Haloperidol • Risperidone • Dexmedetomidine • Benzodiazepines • Sedatives Limitations of current “OFF-LABEL” treatments ▪ Variable Effectiveness ▪ Low quality data supporting use ▪ Significant adverse side-effect profiles Quetiapine: Atypical Antipsychotic • Only available as oral formulation • Slow onset of action (1-2h) • Difficult to administer to delirium patients Oral Quetiapine demonstrated comparative Evidence of Benefit in Delirium patients and a lower side effect profile2 # 8 of the 27 member States of the EU have approved oral and IM Haloperidol for delirium- only if non-pharmacological approaches fail (not for prevention and not for post-operative delirium) 1.. Alghadeer et al., 2024 | 2. Devlin et al., 2010; Oztuzzi et al., 2020 40% 4% 47% 9% Haloperidol Olanzapine Quetiapine Risperidone Oral Quetiapine commonly prescribed1 Quetiapine (QTP) Mechanism of Action in Delirium 7 NQTP (active metabolite): Potent H1, M1–3, NET inhibitor - drives most side effects (sedation, anticholinergic, weight gain). IV dosing minimises NQTP exposure. ↓ Agitation ↓ Nightmares ↓ EPS Risk ↓ Psychosis ↑ Cognition Sleep Improvement Anxiolytic Mood Stabilising Neuroprotection Arousal Circuits Rapid sedation (tolerance develops rapidly) 5-HT / ACh / BDNF Anxiolytic Antidepressant Synaptic plasticity Glutamate Homeostasis ↓ Excitotoxicity Anti-inflammatory Adrenergic / Monoamine ↑ NE in PFC Anxiolysis Nigrostriatal / Mesocortical DA ↓ EPS ↑ PFC dopamine PFC & Hippocampus ↑ DA & NE release improves cognition D2 Antagonist weak, transient 5-HT1A Partial Antagonist CLINICAL OUTCOME DOWNSTREAM PATHWAY DOWNSTREAM PATHWAY CLINICAL OUTCOME ~5-HT Serotonin Dysregulation Glu Glutamate Excess NE Noradrenaline Excess DA Dopamine Excess ACh Acetylcholine Deficit ~H1 Histamine Dysregulation NO IMPACT ON ACh NEUROPROTECTIVE (BDNF) ANTI-INFLAMMATORY (↓ IL-1β, IL-6, and TNF-α) Solution: Proprietary Injectable Quetiapine • Rapid control of acute agitation episodes • Faster resolution of delirium • Improved safety for patients and staff • Shorter ICU and hospital stays • Cost of care reduced 8 Patrys Limited (ASX:PAB) Intellectual Property Protection 8 • Provisional patent application No. 2022901032 • Wholly owned by Patrys with no trailing obligations • New IP developed: Provisional Patent Application filed in 2026 Australia Australian Provisional Patent No. 2022901032 Entered National Phase* Q4 2024 World Intellectual Property Office (WIPO) (PCT/AU2023/050316). • US • EU/UK • Australia Covers • New formulation composition • Method of Use Delirium • Delivery formulation * ~75% of the global pharmaceutical market- 2023 EFPIA. The Pharmaceutical Industry in Figures A Faster Path to Market Reformulation strategy enables faster, de-risked drug development 10 Traditional Drug Development Full Clinical Studies Required High Cost Extensive New Studies Lengthy Process Prolonged Trials & Research High Investment Risk 505(b)(2) Pathway Utilises Existing Safety & Efficacy Data Lower Cost Leverage Existing Data Faster Approval Accelerated Timelines Reduced Time & Expense 2–3X Higher Success Rate vs Novel Drugs 40–60% Lower Cost & Shorter Timeline Risk Factor Risk Typical Biotech This Asset Investor Takeaway Market Demand & Unmet Need • Competing with approved drugs • Must displace established therapies • No approved drug • Clear unmet need in large, growing market Open market with clear demand - no incumbent to displace Intellectual Property Defence • Workarounds feasible • Weak IP • Technical complexity creates a structural barrier for workarounds • Not relying on reg exclusivity (Hatch-Waxman) Defensible IP supports premium valuation and limits competition Manufacturing & Scale-Up Risk • Unproven scale-up • Process risk • Already manufactured at commercial scale • No scale-up required Low execution risk – no scale-up required Regulatory & Reimbursement Risk • Long approval timelines • Payer resistance without clear clinical need • Accelerated reformulation pathway • Established efficacy profile supports reimbursement Clear and accelerated path to approval and reimbursement Clinical & Formulary Adoption • Uncertain reimbursement coverage • Slow adoption timelines • Designed for clinical workflow • Positioned for formulary inclusion Strong adoption potential driven by clinical need and workflow fit A Structurally De-Risked Opportunity 11 Compared to a typical biotech program, this asset is de-risked across all major value drivers HIGH HIGH HIGH HIGH MEDIUM LOW LOW LOW LOW LOW Reformulation Examples 12 Original Indication Reformulated Indication Deal (paracetamol) Chronic pain management (oral) Acute post operative pain management (IV) Ofirmev®: Mallinckrodt $1.4B acquisition Anxiety (1963) Oral tablet Epilepsy (2020) Nasal spray Global Licensing Agreements Schizophrenia (1993) Oral tablet Schizophrenia (2003) Injectable Teva upfront Clinical trial costs $112M in milestones plus royalties Paediatric respiratory infection (Oral) cUTIs (2022) GSK US$66M upfront $525M milestones Oral to IV Examples Successful products specifically reformulated from an oral to i.v. formulation to alleviate acute conditions include: • Zometa®: hypercalcemia of malignancy • Caldolor®: perioperative pain management • Ofirmev®: postoperative pain management • Nexterone®: acute cardiac care In 2024 the FDA approved many (~25) drugs under the 505(b)(2) reformulation pathway. Comparable Reformulations Accelerated Clinical Development Pathway Bridging Studies Required • Human micro-dosing + PBPK modelling • Predict human dose and administration • Leverages existing quetiapine safety data Extensive prior safety data reduces development risk 1.Subjects and Patient numbers are subject to Regulatory and Ethics approvals Phase 1A Clinical Trial • Healthy volunteers1 • PK and safety Phase 1B Study • ICU delirium patients1 • Safety and feasibility • First ICU efficacy data Global pivotal ICU delirium study • Global ICU1 delirium registrational study • Safety and efficacy FDA pre-IND submission FDA IND submission Regulatory approval Pre-Study Preparation • Finalise manufacturing (CMC) • CRO site setup and ethics approvals • Recruit healthy volunteers Potential partnering / licensing point 2026 H1 2026 H2 2027 2028 03 02 01 13 Clinical Development Timeline and Key Value Catalysts Event Target Date Ethics Approval for Phase 1A Q3 2026 Phase 1A trial Initiation Q3 2026 GMP clinical batch release Q4 2026 Phase 1A Completion Q4 2026 FDA pre-IND submission Q1 2027 6 months DP stability for CMC Q1 2027 Ethics approval Phase 1B Q2 2027 Phase 1B first patient dosed Q3 2027 Phase 1B completion Q4 2027 IND submission Q1 2028 Because we are reformulating a drug with extensive clinical history, the bridging studies focus on confirming dosing and clinical safety rather than discovery Multiple near-term clinical and regulatory milestones expected over the next 18–24 months. Extensive existing clinical data Decades of clinical use of oral quetiapine significantly reduces technical and regulatory risk for the IV reformulation program Capital efficient development pathway Key development activities are conducted ahead of and alongside Phase 1A to enable rapid progression into Phase 1B Phase 1A: Dose Confirmation Phase 1A confirms dosing and safety for the IV formulation using the established clinical profile of quetiapine Phase 1B: Safety in ICU setting Phase 1B evaluates safety of the IV formulation in a small number of ICU patients 14 Corporate Snapshot Notes: 1. Shares on issue is shown undiluted. 2. Share price as at 24 July 26 3. Cash balance as per June Quarterly disclosed on 22nd July 2026. Capital Structure Shares on issue 1 674,845,324 Share price 2 3.7c Market capitalisation $25.64M Cash 3 $3.36M Debt Nil Enterprise Value $22.3M Share Price History Market Opportunity ~US$2B Serviceable addressable delirium treatment market 15 Dr. Samantha South Phone: +61 421 117 241 Email: info@patrys.com Patrys Limited (ASX:PAB) patrys.com Contact Proven drug, better delivery. De-risked investment. Patrys Limited (ASX:PAB) Watch online: https://www.youtube.com/watch?v=BNjPXENiSa0 Dr. Samantha South Phone: +61 421 117 241 Email: info@patrys.com Patrys Limited (ASX:PAB) patrys.com Contact Proven drug, better delivery. De-risked investment. Patrys Limited (ASX:PAB) AQS Oral Quetiapine IV Haloperidol IV Dexmedetomide SL Olanzapine Clinical efficacy + + + + + + + +++ Speed of onset + + + + +++ ++ ++ Injectable Quetiapine: Faster Onset. Superior Safety. Current pharmacologic treatments for delirium are used off-label +++ strong / favourable ++ moderate + limited AQS combines rapid onset with a favourable safety profile versus current off-label treatments AQS Oral Quetiapine IV Haloperidol IV Dexmedetomide SL Olanzapine Adverse effects +++ +++ + + + + + Cardiac risk (QTc) +++ +++ + +++ + + Sedation risk ++ +++ + + + + + +++ None / limited ++ Some negative + unfavorable 18 Being assessed IL-6 INHIBITOR MINOCYCLINE Gap in IV Knowledge What we know: Oral pharmacokinetics Know oral dose works delirium (25–100 mg/day) Lower than oral dose schizophrenia >250-800 mg/day Maximum tolerated dose (MTD) of 800-1000 mg/day High oral variability due to first pass metabolism Need to confirm IV starting dose for clinical trial 19